Barclays
ODTX

Barclays’s Odyssey Therapeutics ODTX Stock Holding History

Barclays’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3K Buy
+1,459
New +$25.6K ﹤0.01% 4517

Other funds holding ODTX

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Barclays's ODTX Position: Q2 2026 in Review

Barclays opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 1,459 shares worth $27.3K. The stake represents ﹤0.01% of the portfolio and ranks #4517 among its holdings.

50 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

  • Barclays held 1,459 shares of Odyssey Therapeutics worth $27.3K as of Q2 2026.
  • Odyssey Therapeutics was a new Barclays position in Q2 2026.
  • Odyssey Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4517 holding.
  • 50 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.